See more : Ovintiv Inc. (OVV.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haisco Pharmaceutical Group Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- SpareBank 1 SR-Bank ASA (SRBNK.OL) Income Statement Analysis – Financial Results
- Rede Energia Participações S.A. (REDE3.SA) Income Statement Analysis – Financial Results
- SHAPE Australia Corporation Limited (SHA.AX) Income Statement Analysis – Financial Results
- Cipherloc Corporation (CLOK) Income Statement Analysis – Financial Results
- SLANG Worldwide Inc. (SLGWF) Income Statement Analysis – Financial Results
Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
About Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers small-volume injections, freeze-dried powder injections, powder injections, large-volume injections, active pharmaceutical ingredient, etc. for various therapeutic fields, including anti-infective, digestive system, blood system, nervous system, parenteral nutrition, antibiotics, first aid, anesthetics, and tumor; and tablets, capsules, granules, and ointments in the fields of cardiovascular, anti-infection, digestive system, CNS system, diabetes, and hepatic diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.36B | 3.02B | 2.77B | 3.33B | 3.94B | 3.43B | 1.86B | 1.44B | 1.21B | 1.21B | 992.34M | 802.07M | 604.43M | 581.59M | 484.57M | 358.76M |
| Cost of Revenue | 972.43M | 919.28M | 943.42M | 1.06B | 1.35B | 1.49B | 657.79M | 370.88M | 399.42M | 366.45M | 268.70M | 204.31M | 200.95M | 199.70M | 140.87M | 109.49M |
| Gross Profit | 2.38B | 2.10B | 1.83B | 2.27B | 2.59B | 1.94B | 1.20B | 1.06B | 813.04M | 844.14M | 723.64M | 597.76M | 403.48M | 381.89M | 343.70M | 249.27M |
| Gross Profit Ratio | 71.02% | 69.51% | 65.98% | 68.07% | 65.76% | 56.54% | 64.56% | 74.17% | 67.06% | 69.73% | 72.92% | 74.53% | 66.75% | 65.66% | 70.93% | 69.48% |
| Research & Development | 516.67M | 447.87M | 434.13M | 405.53M | 235.42M | 204.22M | 119.20M | 115.00M | 157.49M | 126.14M | 59.70M | 62.85M | 32.18M | 23.95M | 18.87M | 8.26M |
| General & Administrative | 112.30M | 76.12M | 86.07M | 78.04M | 59.52M | 48.59M | 65.92M | 52.85M | 38.23M | 24.26M | 26.28M | 33.35M | 20.79M | 14.62M | 12.33M | 5.89M |
| Selling & Marketing | 667.84M | 1.14B | 976.33M | 1.27B | 1.71B | 1.33B | 754.38M | 479.37M | 178.18M | 215.54M | 144.40M | 127.78M | 26.68M | 20.49M | 19.23M | 11.74M |
| SG&A | 1.52B | 1.21B | 1.06B | 1.35B | 1.77B | 1.38B | 820.30M | 532.22M | 216.41M | 239.80M | 170.68M | 161.14M | 47.47M | 35.10M | 31.56M | 17.63M |
| Other Expenses | 30.84M | 251.12M | 215.12M | 62.19M | 30.53M | -931.07K | -7.18M | 152.89M | 10.90M | 50.20M | 110.47M | 135.02M | 83.07M | 73.67M | 47.67M | 10.04M |
| Operating Expenses | 2.07B | 1.91B | 1.71B | 1.82B | 2.04B | 1.59B | 975.01M | 774.86M | 472.62M | 455.65M | 306.55M | 276.65M | 122.04M | 93.36M | 77.25M | 38.37M |
| Cost & Expenses | 3.04B | 2.83B | 2.66B | 2.88B | 3.39B | 3.08B | 1.63B | 1.15B | 872.03M | 822.10M | 575.25M | 480.96M | 322.98M | 293.05M | 218.13M | 147.86M |
| Interest Income | 18.87M | 7.69M | 5.58M | 5.41M | 9.96M | 6.56M | 13.39M | 14.94M | 12.41M | 20.40M | 34.74M | 28.88M | 6.64M | 1.38M | 554.65K | 407.24K |
| Interest Expense | 42.28M | 50.91M | 27.16M | 27.29M | 24.15M | 19.80M | 25.48M | 19.08M | 14.71M | 11.58M | 3.36M | 727.04K | 132.85K | 1.59M | 1.83M | 1.72M |
| Depreciation & Amortization | 219.58M | 188.41M | 156.29M | 107.11M | 90.19M | 73.47M | 63.88M | 61.62M | 52.81M | 42.66M | 26.43M | 21.21M | 18.59M | 11.11M | 8.96M | 5.32M |
| EBITDA | 564.39M | 642.78M | 693.98M | 851.73M | 684.51M | 428.61M | 347.43M | 322.41M | 482.81M | 558.79M | 596.89M | 502.44M | 388.11M | 376.58M | 323.46M | 224.18M |
| EBITDA Ratio | 16.82% | 20.12% | 25.04% | 25.27% | 16.89% | 13.02% | 18.54% | 41.36% | 40.04% | 46.29% | 60.66% | 63.08% | 64.47% | 64.38% | 66.78% | 63.11% |
| Operating Income | 313.53M | 364.44M | 512.26M | 698.80M | 546.80M | 323.96M | 265.96M | 347.89M | 405.08M | 454.52M | 461.30M | 348.81M | 287.36M | 290.69M | 269.36M | 207.34M |
| Operating Income Ratio | 9.35% | 12.09% | 18.47% | 20.99% | 13.89% | 9.45% | 14.33% | 24.23% | 33.41% | 37.54% | 46.49% | 43.49% | 47.54% | 49.98% | 55.59% | 57.79% |
| Total Other Income/Expenses | -11.01M | 2.17M | -1.52M | -9.35M | -379.99K | -931.07K | -7.57M | 151.77M | 10.14M | 50.03M | 107.54M | 131.54M | 82.03M | 73.18M | 46.24M | 9.80M |
| Income Before Tax | 302.52M | 366.61M | 510.74M | 689.45M | 546.42M | 323.03M | 258.78M | 500.08M | 415.22M | 504.55M | 568.84M | 480.33M | 369.39M | 363.87M | 315.60M | 217.14M |
| Income Before Tax Ratio | 9.02% | 12.16% | 18.42% | 20.71% | 13.88% | 9.43% | 13.94% | 34.83% | 34.25% | 41.68% | 57.32% | 59.89% | 61.11% | 62.57% | 65.13% | 60.52% |
| Income Tax Expense | 6.96M | -25.03M | -6.84M | 88.25M | 71.56M | 5.49M | 29.68M | 47.43M | 43.06M | 54.01M | 49.62M | 37.27M | 57.09M | 58.12M | 31.88M | 22.05M |
| Net Income | 295.11M | 391.64M | 517.58M | 636.62M | 493.89M | 333.23M | 237.55M | 452.72M | 372.16M | 450.54M | 519.22M | 443.06M | 312.30M | 305.75M | 283.72M | 195.09M |
| Net Income Ratio | 8.80% | 12.99% | 18.66% | 19.12% | 12.54% | 9.72% | 12.80% | 31.54% | 30.69% | 37.22% | 52.32% | 55.24% | 51.67% | 52.57% | 58.55% | 54.38% |
| EPS | 0.26 | 0.36 | 0.48 | 0.60 | 0.46 | 0.31 | 0.22 | 0.41 | 0.35 | 0.42 | 0.48 | 0.41 | 0.32 | 0.32 | 0.31 | 0.21 |
| EPS Diluted | 0.26 | 0.36 | 0.48 | 0.60 | 0.46 | 0.31 | 0.22 | 0.41 | 0.35 | 0.42 | 0.48 | 0.41 | 0.32 | 0.32 | 0.31 | 0.21 |
| Weighted Avg Shares Out | 1.11B | 1.08B | 1.08B | 1.07B | 1.07B | 1.07B | 1.07B | 1.07B | 1.06B | 1.07B | 1.08B | 1.08B | 969.19M | 948.89M | 911.96M | 908.16M |
| Weighted Avg Shares Out (Dil) | 1.11B | 1.08B | 1.08B | 1.07B | 1.07B | 1.07B | 1.08B | 1.08B | 1.06B | 1.07B | 1.08B | 1.08B | 969.19M | 948.89M | 911.96M | 908.16M |
Source: https://incomestatements.info
Category: Stock Reports